BDX — BCAL Diagnostics Share Price
Last trade - 00:00- AU$30.74m
- AU$25.03m
- AU$3.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 3.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.66% | ||
| Return on Equity | -104.23% | ||
| Operating Margin | -326.64% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.44 | 0.28 | 0.7 | 2.79 | 3.05 | n/a | n/a | 64.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BCAL Diagnostics Limited is an Australia-based screening and diagnostic company focused on early diagnosis of breast cancer. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. It is developing diagnostic technology to assist in the early detection of breast cancer by identifying, measuring and validating specific biomarkers enriched in the patient’s blood. It is engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. Its BCAL laboratory employs liquid chromatography mass spectrometry (LCMS) platforms to build on the Company's clinical research and leverage progress. The Company’s BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 15th, 2010
- Public Since
- July 21st, 2021
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 365,967,890
- Address
- Suite 506, Level 5, 50 Clarence Street, SYDNEY, 2000
- Web
- https://www.bcaldiagnostics.com/
- Phone
- Auditors
- Pitcher Partners
Upcoming Events for BDX
Similar to BDX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:31 UTC, shares in BCAL Diagnostics are trading at AU$0.08. This share price information is delayed by 15 minutes.
Shares in BCAL Diagnostics last closed at AU$0.08 and the price had moved by -11.58% over the past 365 days. In terms of relative price strength the BCAL Diagnostics share price has underperformed the ASX All Ordinaries Index by -15.23% over the past year.
There is no consensus recommendation for this security.
Find out moreBCAL Diagnostics does not currently pay a dividend.
BCAL Diagnostics does not currently pay a dividend.
BCAL Diagnostics does not currently pay a dividend.
To buy shares in BCAL Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.08, shares in BCAL Diagnostics had a market capitalisation of AU$30.74m.
Here are the trading details for BCAL Diagnostics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BDX
Based on an overall assessment of its quality, value and momentum BCAL Diagnostics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BCAL Diagnostics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -27.4%.
As of the last closing price of AU$0.08, shares in BCAL Diagnostics were trading -24.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BCAL Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BCAL Diagnostics' management team is headed by:
- Jayne Shaw - CHM
- Guy Robertson - CFO
- Ronald Phillips - NED
- Jonathan Trollip - NID